Օքսիտոցին

main_info

  • trade_name:
  • Օքսիտոցին
  • dosage:
  • 10ԱՄ/մլ(10) ամպուլներ 5մլ, 20մլ, 50մլ և 100մլ ապակե սրվակ
  • pharmaceutical_form:
  • լուծույթ ներարկման
  • prescription_type:
  • Դեղատոմսով
  • medicine_domain:
  • Human
  • medicine_type:
  • Allopathic

documents

localization

  • country:
  • Օքսիտոցին
    አርሜኒያ
  • language:
  • አማርኛ

other_info

status

  • source:
  • Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում - Armenia
  • last_update:
  • 31-05-2018

4-4-2019

FDA expands approved use of metastatic breast cancer treatment to include male patients

FDA expands approved use of metastatic breast cancer treatment to include male patients

The FDA is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients.

FDA - U.S. Food and Drug Administration

12-6-2018

Dave’s Pet Food Voluntarily Recalls 95% Premium Beef Canned Dog Food Due to Potentially Elevated Levels of Thyroid Hormone

Dave’s Pet Food Voluntarily Recalls 95% Premium Beef Canned Dog Food Due to Potentially Elevated Levels of Thyroid Hormone

Dave’s Pet Food of Agawam, MA is recalling a single lot of Dave’s Dog Food 95% premium beef cans because the products potentially contain elevated levels of beef thyroid hormone.

FDA - U.S. Food and Drug Administration

23-5-2018

Merrick Pet Care Voluntarily Recalls Limited Amount of Good Buddy and Backcountry Treats Containing Beef Due to Potentially Elevated Levels of Thyroid Hormone

Merrick Pet Care Voluntarily Recalls Limited Amount of Good Buddy and Backcountry Treats Containing Beef Due to Potentially Elevated Levels of Thyroid Hormone

Merrick Pet Care, of Amarillo, Texas, is initiating a voluntary recall of a limited amount of beef dog treat varieties due to the potential that they contain elevated levels of a naturally-occurring beef thyroid hormone.

FDA - U.S. Food and Drug Administration

6-5-2014

Guidance material to doctors and users of contraceptive pills

Guidance material to doctors and users of contraceptive pills

The EU Pharmacovigilance Risk Assessment Committee (PRAC) recently completed a review of the risk of blood clots (VTE) with contraceptive pills and other combined hormonal contraceptives. Combined hormonal contraceptives contain two types of hormone, oestrogen and progesterone, and are available as pills, transdermal patches and vaginal rings.

Danish Medicines Agency

8-3-2019

EU/3/08/545 (Clinuvel Europe Limited)

EU/3/08/545 (Clinuvel Europe Limited)

EU/3/08/545 (Active substance: [Nle4, D-Phe7]-alpha-melanocyte stimulating hormone) - Transfer of orphan designation - Commission Decision (2019)1948 of Fri, 08 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004293

Europe -DG Health and Food Safety

8-3-2019

EU/3/08/541 (Clinuvel Europe Limited)

EU/3/08/541 (Clinuvel Europe Limited)

EU/3/08/541 (Active substance: [Nle4, D-Phe7]-alpha-melanocyte stimulating hormone) - Transfer of orphan designation - Commission Decision (2019)1947 of Fri, 08 Mar 2019 European Medicines Agency (EMA) procedure number: EMA/OD/0000004019

Europe -DG Health and Food Safety

21-2-2019


Orphan designation: Recombinant human growth hormone modified by fusion with two hydrophilic polypeptide chains (somavaratan), Treatment of growth-hormone deficiency, 05/08/2013, Withdrawn

Orphan designation: Recombinant human growth hormone modified by fusion with two hydrophilic polypeptide chains (somavaratan), Treatment of growth-hormone deficiency, 05/08/2013, Withdrawn

Orphan designation: Recombinant human growth hormone modified by fusion with two hydrophilic polypeptide chains (somavaratan), Treatment of growth-hormone deficiency, 05/08/2013, Withdrawn

Europe - EMA - European Medicines Agency

17-1-2019

Natpar (Shire Pharmaceuticals Ireland Limited)

Natpar (Shire Pharmaceuticals Ireland Limited)

Natpar (Active substance: parathyroid hormone) - PSUSA - Modification - Commission Decision (2019)269 of Thu, 17 Jan 2019 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10591/201804

Europe -DG Health and Food Safety

19-12-2018


Orphan designation: Somapacitan, Treatment of growth hormone deficiency, 24/08/2018, Positive

Orphan designation: Somapacitan, Treatment of growth hormone deficiency, 24/08/2018, Positive

Orphan designation: Somapacitan, Treatment of growth hormone deficiency, 24/08/2018, Positive

Europe - EMA - European Medicines Agency

19-12-2018

EU/3/12/1087 (Richardson Associates Regulatory Affairs Ltd)

EU/3/12/1087 (Richardson Associates Regulatory Affairs Ltd)

EU/3/12/1087 (Active substance: Recombinant modified human growth hormone) - Transfer of orphan designation - Commission Decision (2018)9014 of Wed, 19 Dec 2018 European Medicines Agency (EMA) procedure number: EMA/OD/0000002652

Europe -DG Health and Food Safety